Q32 Bio reports Q2 net loss of $17.0M; bempikibart AD trial enrollment completed at 121 patients

Q32 Bio Inc.

2024-Q2 EPS reported -$4.44

Net loss $17.0M ($1.42/share) vs $5.8M ($16.69) in Q2 2023; R&D expense rose to $13.4M from $8.0M.
Cash and investments $107.6M as of June 30; expected funding into mid-2026.
Completed enrollment in bempikibart AD Phase 2 trial (121 patients); topline results on track for Q4 2024.
ADX-097 Phase 2 basket trial for renal diseases enrolling; initial open-label data expected by year-end 2024.
Bempikibart AA Phase 2 topline results also expected in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.